Retatrutide
GLP-1Overview
A triple GLP-1/GIP/glucagon receptor agonist studied for potent weight reduction and metabolic research.
Mechanism of Action
Retatrutide is described in preclinical and clinical research as a triple agonist at the GLP-1, GIP, and glucagon receptors. This multi-receptor activity is thought to influence appetite signaling, energy balance, and glucose-related pathways, which may underlie its effects on body weight and metabolic markers.
Reported Research Observations
Researchers have observed substantial weight reduction and changes in metabolic parameters in study settings, consistent with its combined incretin and glucagon receptor activity. It has also been studied for effects on glycemic control, appetite regulation, and broader cardiometabolic research endpoints.
Quick Facts
- Commonly Available Vial Sizes
- 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 100 mg
- Typical Research Dose
- 500 – 12,000 mcg
- Suggested BAC Water
- 1 mL
- Category
- GLP-1
Safety & Handling
Retatrutide is a research-use-only compound and is not approved for general clinical use in this context. Handling should follow standard laboratory practices; if a study protocol requires reconstitution, researchers commonly use bacteriostatic water under sterile conditions and store prepared material refrigerated according to local stability guidance. As with other peptide reagents, integrity, purity, and contamination control should be verified before experimental use.
Notes
Available in 5mg to 60mg vials | Dosing: Once weekly, 48 weeks (Phase 2); ongoing anticipated. Route: Subcutaneous (SC)
Commonly Researched Together
Further Reading
For laboratory and research use only. Not for human consumption or clinical use. Information is provided for reference and does not constitute medical advice.